List of Excipients in Branded Drug COLCRYS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AR Scientific Inc	COLCRYS	colchicine	13310-119	CARNAUBA WAX
AR Scientific Inc	COLCRYS	colchicine	13310-119	CELLULOSE, MICROCRYSTALLINE
AR Scientific Inc	COLCRYS	colchicine	13310-119	FD&C BLUE NO. 2
AR Scientific Inc	COLCRYS	colchicine	13310-119	FD&C RED NO. 40
AR Scientific Inc	COLCRYS	colchicine	13310-119	HYPROMELLOSES
AR Scientific Inc	COLCRYS	colchicine	13310-119	LACTOSE MONOHYDRATE
AR Scientific Inc	COLCRYS	colchicine	13310-119	MAGNESIUM STEARATE

Colcrys Excipient Strategy and Commercial Opportunities in Colchicine Tablets

Last updated: August 2, 2026

Colcrys is an immediate-release 0.6 mg colchicine tablet marketed in the United States by Takeda Pharmaceuticals. Its commercial value depends less on novel excipients than on dose uniformity, dissolution control, tablet manufacturability, supply reliability, and regulatory differentiation. Generic colchicine has reduced pricing power, but opportunities remain in pediatric liquids, renal- and hepatic-risk dosing, abuse-resistant packaging, optimized low-dose products, international markets, and differentiated 505(b)(2) formulations.

What is Colcrys and how is it regulated?

Colcrys contains colchicine, an anti-inflammatory drug approved for acute gout flares, gout prophylaxis, and familial Mediterranean fever. The product is approved under FDA New Drug Application 022352. The FDA approved Colcrys in July 2009 after determining that the product met applicable safety, efficacy, quality, and labeling requirements for colchicine use.[1]

Colchicine has a narrow therapeutic margin. Toxicity can involve gastrointestinal injury, myelosuppression, neuromuscular effects, multiorgan failure, and death. Exposure increases with renal or hepatic impairment and with inhibitors of CYP3A4 or P-glycoprotein.[1] These characteristics materially affect excipient selection, dissolution specifications, packaging, and product-positioning strategy.

Attribute	Colcrys profile
Active ingredient	Colchicine
Strength	0.6 mg
Dosage form	Immediate-release film-coated tablet
U.S. regulatory application	NDA 022352
Main indications	Gout flares, gout prophylaxis, familial Mediterranean fever
Primary manufacturers/marketers	Takeda Pharmaceuticals and authorized or licensed generic manufacturers
Generic pathway	Abbreviated New Drug Application, subject to Orange Book patent and exclusivity conditions
Biosimilar pathway	Not applicable
Primary technical risk	Dose uniformity and exposure control for a narrow-therapeutic-index drug

Colcrys is a small-molecule product. Biosimilar competition is therefore irrelevant. Competitive entry occurs through generic colchicine, authorized generics, and potentially reformulated products approved through the 505(b)(2) pathway.

What excipients are used in Colcrys tablets?

The Colcrys label identifies a conventional solid-oral excipient system. The tablet core uses lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and stearic acid. The film coating contains hypromellose, titanium dioxide, and colorants.[1]

Functional role of the Colcrys excipients

Excipient	Primary function	Commercial or technical relevance
Lactose monohydrate	Diluent and bulking agent	Supports low-dose tablet manufacture; requires attention to lactose intolerance and supplier consistency
Microcrystalline cellulose	Diluent and compression aid	Improves tablet strength and manufacturability at a low active load
Sodium starch glycolate	Superdisintegrant	Promotes rapid tablet breakup and immediate release
Stearic acid	Lubricant	Supports ejection from the tablet press; excessive levels can slow dissolution
Hypromellose	Film former	Protects the tablet and provides a uniform coating surface
Titanium dioxide	Opacifier and pigment	Supports appearance and light protection
Colorants	Product identification	Useful for brand recognition and strength differentiation

The principal formulation challenge is the very small colchicine dose. A 0.6 mg tablet requires reliable content uniformity despite the relatively large mass of excipients. Manufacturers must control active-particle size, blending segregation, geometric dilution, granulation behavior, and compression performance.

What excipient strategy is best for generic colchicine?

The lowest-risk generic strategy is a conventional immediate-release tablet that matches the reference product's critical quality attributes without copying every excipient. FDA-approved generics may use different inactive ingredients if the product meets bioequivalence, quality, safety, and labeling requirements.[2]

A generic manufacturer should prioritize five controls:

1. Content uniformity. Colchicine distribution must remain consistent across the blend and throughout tableting.
2. Dissolution. Lubricant concentration, disintegrant grade, compression force, and coating weight can materially affect release.
3. Particle engineering. Controlled particle size can reduce segregation and improve blend uniformity.
4. Moisture management. Lactose, starch-based disintegrants, and hypromellose coatings require controlled humidity during processing and storage.
5. Packaging protection. Unit-dose blister packaging can reduce medication errors and help maintain product identity in polypharmacy settings.

The commercial advantage of a conventional formulation is regulatory familiarity and lower development cost. The disadvantage is limited differentiation and substantial price competition.

Which excipient substitutions create the most value?

Potential substitutions include:

• Replacing lactose with mannitol, dibasic calcium phosphate, or another diluent for lactose-free positioning.
• Replacing sodium starch glycolate with crospovidone or croscarmellose sodium to alter disintegration behavior.
• Using a different film-coating system to improve color stability, moisture resistance, or swallowing characteristics.
• Using direct-compression grades of microcrystalline cellulose to reduce process steps.
• Using a co-processed excipient to improve low-dose content uniformity.

Excipient substitution alone does not create a strong commercial moat. The value arises when the substitution improves a measurable attribute, such as tablet robustness, lower variability, reduced moisture sensitivity, easier swallowing, or a clinically useful dosage form.

What formulation opportunities exist beyond the Colcrys tablet?

Pediatric and geriatric oral liquids

A ready-to-use oral solution or suspension could address patients who cannot swallow tablets, including children, older adults, and patients with feeding tubes. A liquid product would need strict control of:

• Colchicine solubility and physical stability.
• Uniform concentration throughout shelf life.
• Palatability and bitterness.
• Preservative compatibility.
• Dosing-device accuracy.
• Child-resistant and senior-friendly packaging.

Colchicine toxicity makes dosing-device performance commercially important. A calibrated oral syringe is more defensible than a household spoon-based presentation. A liquid could qualify for 505(b)(2) development if the sponsor relies on FDA findings for the established colchicine drug while generating product-specific safety, stability, and pharmacokinetic data.

Orally disintegrating tablets

An orally disintegrating tablet could improve administration for patients with dysphagia. The formulation would need rapid disintegration without creating unacceptable bitterness. Taste-masking approaches could include polymeric barriers, ion-exchange resins, coated drug particles, or sweetener and flavor systems.

The principal risk is that taste-masking excipients or hydrophobic coatings may delay dissolution. Any orally disintegrating product must preserve rapid and predictable colchicine release.

Lower-dose tablets

A 0.3 mg tablet could support more precise titration for patients with renal impairment, hepatic impairment, drug interactions, or increased toxicity risk. The technical challenge is greater content-uniformity risk at a lower active load. A lower-strength tablet could also reduce tablet splitting and dosing errors.

The commercial case is strongest if the product is supported by dosing guidance, packaging that limits accidental duplicate dosing, and a regulatory strategy focused on a defined clinical need rather than simple line extension.

Modified-release and multiparticulate systems

Modified-release colchicine could theoretically reduce peak exposure or improve adherence. Its commercial attractiveness is lower than that of liquid or lower-dose products because colchicine is commonly used for acute flares, where rapid availability is important.

Multiparticulate systems may offer improved dose flexibility, but they introduce manufacturing, bioequivalence, and dose-dumping questions. A modified-release product would require a clear clinical or adherence benefit to justify development costs.

What patent protection covers Colcrys and its excipient strategy?

Colcrys protection has historically relied on patents covering colchicine dosing regimens, methods of treating gout, and related product claims, rather than a broad proprietary excipient platform. The FDA Orange Book is the controlling source for current listed patents, pediatric exclusivity, and any applicable regulatory exclusivity.[3]

The commercial implications are:

• Conventional generic tablets can challenge listed patents through ANDA Paragraph IV certifications.
• Method-of-use patents may be avoided through a Section viii statement when the generic label omits the protected indication, subject to FDA and litigation constraints.
• Excipients that are already used in ordinary pharmaceutical manufacturing generally provide weak standalone patent protection.
• A differentiated formulation may support patent claims if it includes a novel composition, defined excipient ratio, controlled-release structure, taste-masking architecture, or manufacturing process.
• A formulation patent is more valuable when it produces a measurable pharmaceutical advantage, such as improved stability, reduced variability, or a clinically meaningful pharmacokinetic profile.

When does Colcrys lose exclusivity?

Colcrys no longer has practical market exclusivity based solely on brand status because FDA-approved generic colchicine products are available. The relevant commercial question is the status of current Orange Book patents and any settlement restrictions affecting particular generic applicants.

Patent expiration dates can vary by patent, pediatric extensions, terminal disclaimers, and litigation outcomes. A current Orange Book review is required for transaction, launch, or Paragraph IV decisions. The FDA Orange Book should be reviewed by NDA 022352 and patent-use-code entry before relying on an expiration date.[3]

What Paragraph IV and litigation risks affect generic colchicine?

A generic applicant filing a Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. The filing can trigger patent litigation under the Hatch-Waxman framework and may create a 30-month FDA approval stay if the reference-product sponsor files suit within the statutory period.[4]

For colchicine, litigation risk is concentrated in:

• Low-dose treatment regimens.
• Gout prophylaxis methods.
• Familial Mediterranean fever use.
• Label carve-outs and skinny-label strategies.
• Product-by-process or formulation claims.
• Settlement terms governing launch dates.

A generic applicant can reduce risk by pursuing a non-infringing label, challenging weak method claims, or selecting a formulation with different excipient composition. A sponsor developing a reformulated product should avoid assuming that a new excipient system eliminates method-of-use exposure.

What settlement agreements matter?

Settlement agreements between the reference-product sponsor and generic applicants can determine launch timing even where patents remain listed. Terms may include:

• An agreed generic-entry date.
• Authorized-generic supply arrangements.
• Royalty payments.
• Restrictions on specific indications.
• Covenants not to sue.
• Manufacturing or distribution rights.

Settlement terms may not be fully apparent from the Orange Book. They may appear in FTC submissions, court dockets, SEC filings, or company disclosures. Any investment or licensing analysis should separate patent expiration from contractual launch rights.

What FDA pathway is available for a differentiated colchicine product?

A conventional generic tablet normally proceeds through an ANDA. A new oral liquid, orally disintegrating tablet, or modified-release product may require a 505(b)(2) NDA if the sponsor relies in part on FDA findings for colchicine while submitting new product-specific data.[5]

Product concept	Likely pathway	Main evidence burden
Conventional 0.6 mg tablet	ANDA	Bioequivalence, CMC, stability, labeling
Lactose-free immediate-release tablet	ANDA if substitutable	Bioequivalence and inactive-ingredient justification
Oral solution	505(b)(2) or ANDA depending on reference and product design	Stability, dose uniformity, palatability, pharmacokinetics
Orally disintegrating tablet	505(b)(2) or ANDA	Disintegration, dissolution, taste, bioequivalence
0.3 mg tablet	505(b)(2) or ANDA depending on reference pathway	Content uniformity, bioequivalence, dosing justification
Modified-release colchicine	505(b)(2)	Pharmacokinetics, food effect, release control, safety

FDA's inactive-ingredient framework allows excipient changes within regulatory limits, but the sponsor remains responsible for safety, quality, and bioequivalence.[2]

Which companies are positioned to challenge Colcrys?

The competitive field includes:

• Generic manufacturers with approved colchicine tablets.
• Authorized-generic suppliers linked to the reference-product sponsor.
• Contract manufacturers with low-dose oral-solid-dose expertise.
• Specialty pharmaceutical companies developing liquid or pediatric formulations.
• International manufacturers seeking U.S. ANDA or 505(b)(2) entry.

The strongest generic competitors are those that can manufacture low-dose tablets at high yield while maintaining content uniformity and dissolution. The strongest differentiated-product competitors are those with oral-liquid, taste-masking, packaging, and specialty-pharmacy capabilities.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can participate through performance-based formulation support rather than commodity supply alone. The most attractive opportunities are:

• Direct-compression excipient systems for low-dose tablets.
• Low-moisture excipients for improved stability.
• Co-processed excipients that reduce blend segregation.
• Taste-masking polymers for oral liquids and orally disintegrating tablets.
• Ready-to-use film-coating systems.
• Excipient packages compatible with automated content-uniformity testing.
• Technical support for scale-up, process validation, and regulatory documentation.

A supplier with a proprietary excipient grade may obtain stronger negotiating leverage through formulation know-how, process data, and regulatory files. The excipient itself is rarely sufficient to create durable exclusivity.

How strong is the Colcrys patent estate?

The estate is commercially meaningful but narrower than a platform estate based on multiple independent formulation technologies. Its value depends on the surviving scope of method-of-use and formulation claims, the exact Orange Book entries, and the ability to enforce those claims against generic labels.

Estate component	Strategic strength
Brand recognition and clinical history	Moderate
Conventional tablet formulation	Low to moderate
Dosing and method-of-use claims	Potentially meaningful, depending on claim scope
Excipient exclusivity	Limited unless supported by novel composition claims
Manufacturing barriers	Moderate for low-dose content uniformity
Generic substitution barriers	Low after generic approval
Pediatric liquid opportunity	High relative to the conventional tablet
Biosimilar protection	Not applicable

What revenue exposure does generic competition create?

Generic entry typically compresses price, market share, and gross margin for the branded product. The impact is highest in chronic gout prophylaxis, where recurring prescriptions are easily substituted. Brand value can persist in physician familiarity, supply reliability, patient support, and managed-care positioning, but these advantages weaken as multiple generic suppliers enter.

The most defensible commercial opportunities are products that solve a specific administration or dosing problem:

• Pediatric oral liquid.
• 0.3 mg precision-dose tablet.
• Unit-dose packaging for high-risk patients.
• Taste-masked dosage forms.
• Formulations designed for feeding-tube administration.
• International products adapted to local excipient and packaging requirements.

Key Takeaways

• Colcrys is a 0.6 mg immediate-release colchicine film-coated tablet approved under NDA 022352.
• Its core excipients are conventional and include lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and stearic acid.
• The main formulation risk is content uniformity caused by the very low colchicine dose.
• Excipient substitution can improve manufacturability, stability, swallowing, or taste, but it does not automatically create patent protection.
• Generic competition is established; biosimilar competition is irrelevant because colchicine is a small molecule.
• The strongest product opportunities are oral liquids, orally disintegrating tablets, lower-dose tablets, and dosing-error-resistant packaging.
• Current Orange Book patents, patent-use codes, Paragraph IV certifications, and settlement agreements must be reviewed before assigning a launch date or litigation risk.
• A conventional generic normally uses the ANDA pathway. A differentiated dosage form may require a 505(b)(2) NDA.
• Excipient suppliers have the best commercial leverage when they provide formulation, scale-up, and regulatory support together with the excipient.

FAQs

Can a lactose-free colchicine tablet compete directly with Colcrys?

Yes. A lactose-free generic or reformulated product could target patients and prescribers seeking an alternative excipient profile, but it would still need to satisfy FDA quality and bioequivalence requirements.

Is colchicine suitable for an extended-release formulation?

It is technically possible, but the commercial case is uncertain because acute gout treatment requires timely exposure. A modified-release product would need a clear pharmacokinetic, safety, or adherence advantage.

Could an oral colchicine solution receive pediatric exclusivity?

A liquid product could support pediatric development and may qualify for pediatric exclusivity if FDA requirements are met. The product would need pediatric clinical or regulatory support, not merely a new flavor or bottle.

Does a different excipient formula avoid Colcrys patents?

Not necessarily. A different excipient system may avoid composition claims but can still implicate method-of-use, dosage, manufacturing, or other listed patent claims.

What is the most attractive commercial niche for a new colchicine product?

A low-dose, accurately measured, taste-masked oral liquid is among the strongest niches because it addresses swallowing limitations, pediatric use, dose precision, and administration risk more directly than another conventional 0.6 mg tablet.

References

1. U.S. Food and Drug Administration. (2009). Colcrys prescribing information. NDA 022352.
2. U.S. Food and Drug Administration. (2014). Inactive ingredient database. Center for Drug Evaluation and Research.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).
5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). Center for Drug Evaluation and Research.